Awakn Life Sciences (TSE:AWKN) has released an update.
Awakn Life Sciences has expanded its Phase 3 trial sites for its investigational treatment AWKN-001, targeting severe alcohol use disorder, by adding four new locations in the UK. This expansion is part of the MORE-KARE study, which seeks to evaluate the efficacy of ketamine-assisted therapy in reducing alcohol relapse. The trial, supported by prominent UK research institutions, aims to offer a novel treatment pathway for individuals suffering from severe alcohol use disorder.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.
